Phase 1 Dose-Escalation Study of Pegylated Arginine Deiminase, Cisplatin, and Pemetrexed in Patients With Argininosuccinate Synthetase 1–Deficient Thoracic Cancers

PURPOSE: Pegylated arginine deiminase (ADI-PEG 20) depletes essential amino acid levels in argininosuccinate synthetase 1 (ASS1) –negative tumors by converting arginine to citrulline and ammonia. The main aim of this study was to determine the recommended dose, safety, and tolerability of ADI-PEG 20...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Clin Oncol
Hlavní autoři: Beddowes, Emma, Spicer, James, Chan, Pui Ying, Khadeir, Ramsay, Corbacho, Javier Garcia, Repana, Dimitra, Steele, Jeremy P., Schmid, Peter, Szyszko, Teresa, Cook, Gary, Diaz, Monica, Feng, Xiaoxing, Johnston, Amanda, Thomson, Jim, Sheaff, Michael, Wu, Bor-Wen, Bomalaski, John, Pacey, Simon, Szlosarek, Peter W.
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Clinical Oncology 2017
Témata:
ORIGINAL REPORTS
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6141244/
https://ncbi.nlm.nih.gov/pubmed/28388291
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2016.71.3230
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky